{"id":127586,"date":"2024-03-12T07:59:29","date_gmt":"2024-03-12T11:59:29","guid":{"rendered":"http:\/\/kendallharmon.net\/?p=127586"},"modified":"2024-03-12T17:54:46","modified_gmt":"2024-03-12T21:54:46","slug":"sa-parkinsons-drug-reduces-disease-markers-in-breakthrough-trial","status":"publish","type":"post","link":"https:\/\/kendallharmon.net\/?p=127586","title":{"rendered":"(SA) Parkinson&#8217;s Drug Reduces Disease Markers in Breakthrough Trial"},"content":{"rendered":"<p>A novel therapy designed to clear toxic clumps of a protein thought to be responsible for Parkinson&#8217;s disease has shown promise in early clinical trials.<\/p>\n<p>Produced by the US biotechnology company Vaxxinity, the immunotherapy candidate codenamed UB-312 is the first treatment shown to be capable of reducing concentrations of alpha-synuclein (\u03b1-syn) in cerebrospinal fluid, marking a significant step forward in slowing \u2013 or even halting \u2013 the disorder&#8217;s progress.<\/p>\n<p>Though the results of the trial are yet to be published and peer reviewed, reports from company officials are optimistic, suggesting they&#8217;re onto something big.<\/p>\n<p><a href=\"https:\/\/www.sciencealert.com\/parkinsons-drug-reduces-disease-markers-in-breakthrough-trial\">Read it all<\/a>.<\/p>\n<blockquote class=\"twitter-tweet\">\n<p lang=\"en\" dir=\"ltr\">&quot;Analysis of the spinal fluid of those given UB-312 revealed a 20 percent drop in their usual \u03b1-syn aggregate levels, compared with a 3 percent decline in those who received a placebo.&quot;<a href=\"https:\/\/twitter.com\/hashtag\/Parkinsons?src=hash&amp;ref_src=twsrc%5Etfw\">#Parkinsons<\/a><a href=\"https:\/\/twitter.com\/hashtag\/longcovid?src=hash&amp;ref_src=twsrc%5Etfw\">#longcovid<\/a> <a href=\"https:\/\/t.co\/BAdtKw2Dj8\">https:\/\/t.co\/BAdtKw2Dj8<\/a><\/p>\n<p>&mdash; Troy Roach (@Canal1point5) <a href=\"https:\/\/twitter.com\/Canal1point5\/status\/1767555114825560303?ref_src=twsrc%5Etfw\">March 12, 2024<\/a><\/p><\/blockquote>\n<p> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A novel therapy designed to clear toxic clumps of a protein thought to be responsible for Parkinson&#8217;s disease has shown promise in early clinical trials. Produced by the US biotechnology company Vaxxinity, the immunotherapy candidate codenamed UB-312 is the first<span class=\"ellipsis\">&hellip;<\/span><\/p>\n<div class=\"read-more\"><a href=\"https:\/\/kendallharmon.net\/?p=127586\">Read more &#8250;<\/a><\/div>\n<p><!-- end of .read-more --><\/p>\n","protected":false},"author":794,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[104,95],"tags":[],"class_list":["post-127586","post","type-post","status-publish","format-standard","hentry","category-health-medicine","category-science-technology"],"_links":{"self":[{"href":"https:\/\/kendallharmon.net\/index.php?rest_route=\/wp\/v2\/posts\/127586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kendallharmon.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kendallharmon.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kendallharmon.net\/index.php?rest_route=\/wp\/v2\/users\/794"}],"replies":[{"embeddable":true,"href":"https:\/\/kendallharmon.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=127586"}],"version-history":[{"count":3,"href":"https:\/\/kendallharmon.net\/index.php?rest_route=\/wp\/v2\/posts\/127586\/revisions"}],"predecessor-version":[{"id":127589,"href":"https:\/\/kendallharmon.net\/index.php?rest_route=\/wp\/v2\/posts\/127586\/revisions\/127589"}],"wp:attachment":[{"href":"https:\/\/kendallharmon.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=127586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kendallharmon.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=127586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kendallharmon.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=127586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}